206 related articles for article (PubMed ID: 32909660)
21. OX40L blockade and allergen-induced airway responses in subjects with mild asthma.
Gauvreau GM; Boulet LP; Cockcroft DW; FitzGerald JM; Mayers I; Carlsten C; Laviolette M; Killian KJ; Davis BE; Larché M; Kipling C; Dua B; Mosesova S; Putnam W; Zheng Y; Scheerens H; McClintock D; Matthews JG; O'Byrne PM
Clin Exp Allergy; 2014 Jan; 44(1):29-37. PubMed ID: 24224471
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.
Ortega H; Fitzgerald M; Raghupathi K; Tompkins CA; Shen J; Dittrich K; Pattwell C; Singh D
Clin Exp Allergy; 2020 Feb; 50(2):189-197. PubMed ID: 31659803
[TBL] [Abstract][Full Text] [Related]
23. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
24. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
[TBL] [Abstract][Full Text] [Related]
25. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
26. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
De Boever EH; Ashman C; Cahn AP; Locantore NW; Overend P; Pouliquen IJ; Serone AP; Wright TJ; Jenkins MM; Panesar IS; Thiagarajah SS; Wenzel SE
J Allergy Clin Immunol; 2014 Apr; 133(4):989-96. PubMed ID: 24582316
[TBL] [Abstract][Full Text] [Related]
28. HFA-BDP Metered-Dose Inhaler Exhaled Through the Nose Improves Eosinophilic Chronic Rhinosinusitis With Bronchial Asthma: A Blinded, Placebo-Controlled Study.
Kobayashi Y; Yasuba H; Asako M; Yamamoto T; Takano H; Tomoda K; Kanda A; Iwai H
Front Immunol; 2018; 9():2192. PubMed ID: 30337921
[No Abstract] [Full Text] [Related]
29. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
30. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
31. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.
Kelsen SG; Agache IO; Soong W; Israel E; Chupp GL; Cheung DS; Theess W; Yang X; Staton TL; Choy DF; Fong A; Dash A; Dolton M; Pappu R; Brightling CE
J Allergy Clin Immunol; 2021 Sep; 148(3):790-798. PubMed ID: 33872652
[TBL] [Abstract][Full Text] [Related]
32. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.
Samitas K; Delimpoura V; Zervas E; Gaga M
Eur Respir Rev; 2015 Dec; 24(138):594-601. PubMed ID: 26621973
[TBL] [Abstract][Full Text] [Related]
33. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
34. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
37. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma.
van den Toorn LM; Prins JB; de Jongste JC; Leman K; Mulder PG; Hoogsteden HC; Overbeek SE
Respir Med; 2005 Jun; 99(6):779-87. PubMed ID: 15878496
[TBL] [Abstract][Full Text] [Related]
38. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
39. Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H
Kollmeier AP; Greenspan A; Xu XL; Silkoff PE; Barnathan ES; Loza MJ; Jiang J; Zhou B; Chen B; Thurmond RL
Clin Exp Allergy; 2018 Aug; 48(8):957-969. PubMed ID: 29682796
[TBL] [Abstract][Full Text] [Related]
40. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
